Department of Pharmacy, Quanzhou Medical College, Quanzhou, Fujian, China.
Nephrology Department, Quanzhou Hospital of Traditional Chinese Medicine, Quanzhou, Fujian, China.
Medicine (Baltimore). 2024 Nov 1;103(44):e40391. doi: 10.1097/MD.0000000000040391.
Asthma is a serious public health challenge around the world. Recent studies into traditional Chinese medicine preparations for asthma have yielded promising findings regarding Bailing Capsule's potential in bronchial asthma prevention and treatment. This study aims to initially clarify the potential mechanism of Bailing Capsule in the treatment of asthma using network pharmacology and in vitro experimental approaches. Network pharmacology was adopted to detect the active ingredients of Bailing Capsule via Traditional Chinese Medicine Systems Pharmacology Database, and the key targets and signaling pathways in the treatment of asthma were predicted. Docking and molecular dynamics simulations were conducted to verify the most important interactions formed by these probes within different regions of the binding site. The predicted targets were validated in lipopolysaccharide-induced 16HBE cell experiment. Seven active ingredients were screened from Bailing Capsule, 294 overlapping targets matched with asthma were considered potential therapeutic targets, such as SRC, TP53, STAT3, and E1A binding protein P300. The main functional pathways involving these key targets include phosphatidylinositol 3-kinase/protein kinase B, mitogen-activated protein kinase, renin-angiotensin system and other signaling pathways, which were mainly involved in the inflammatory response, apoptosis, and xenobiotic stimulus. Moreover, molecular docking showed that Cerevisterol have higher affinity for SRC, TP53, STAT3, and E1A binding protein P300 than other main active components, which is close to the docking results of the co-crystallized ligands to proteins. Consequently, Cerevisterol was selected for molecular dynamics simulation and the results show that Cerevisterol can bind most tightly to SRC, TP53, and STAT3. Bailing Capsule can promote the growth of 16HBE cell, reduce the production of IL-4, TNF-α and IL-6, and down-regulate the levels of SRC and STAT3 mRNA. This study preliminarily reveals the potential mechanism of Bailing Capsule against asthma with the aid of network pharmacology and in vitro cell experiment, which provided reference and guidance for in-depth research and clinical application.
哮喘是全球范围内严重的公共卫生挑战。最近对中药制剂治疗哮喘的研究发现,百令胶囊在支气管哮喘的防治方面具有潜在作用。本研究采用网络药理学和体外实验方法,初步探讨百令胶囊治疗哮喘的潜在作用机制。采用中药系统药理学数据库分析百令胶囊的活性成分,预测治疗哮喘的关键靶点和信号通路。通过对接和分子动力学模拟验证这些探针在结合部位不同区域形成的最重要相互作用。在脂多糖诱导的 16HBE 细胞实验中验证预测的靶点。从百令胶囊中筛选出 7 种活性成分,294 个与哮喘相关的重叠靶点被认为是潜在的治疗靶点,如 SRC、TP53、STAT3 和 E1A 结合蛋白 P300。涉及这些关键靶点的主要功能途径包括磷脂酰肌醇 3-激酶/蛋白激酶 B、丝裂原活化蛋白激酶、肾素-血管紧张素系统等信号通路,主要涉及炎症反应、细胞凋亡和外源刺激。此外,分子对接表明,麦角甾醇与 SRC、TP53、STAT3 和 E1A 结合蛋白 P300 的亲和力高于其他主要活性成分,与蛋白配体的对接结果相近。因此,选择麦角甾醇进行分子动力学模拟,结果表明麦角甾醇能与 SRC、TP53 和 STAT3 结合得最紧密。百令胶囊能促进 16HBE 细胞生长,降低 IL-4、TNF-α和 IL-6 的产生,下调 SRC 和 STAT3mRNA 的水平。本研究借助网络药理学和体外细胞实验初步揭示了百令胶囊治疗哮喘的潜在作用机制,为深入研究和临床应用提供了参考和指导。